European Society of Gene and Cell Therapy

This characteristic serves as the premise for a specific debate, which we'll investigate thanks to the question of a very well-prepared listener who asked In Europe, when will regulators allow the reuse of clinical data from gene editors across different mutations within the same gene?

I'm also the president of the European Society of Gene Therapy.

One of the discussions that we're having with regulators is how to have a process where we still provide all the main evidences of the safety of our product because we cannot make any discount on that part.

But at the same time, we can expedite the development of a product based on the data that have been, including clinical data that have been produced with that same approach and platform.